| 39.37 Delayed Data As of Apr 24 |  -0.05 / -0.13%Today’s Change | 34.37 Today|||52-Week Range 46.47 | -9.81% Year-to-Date |
| Previous close | 39.42 |
| Today’s open | 39.50 |
| Day’s range | 39.16 - 39.64 |
| Volume | 20,110,959 |
| Average volume (3 months) | 25,310,394 |
| Market cap | $218.6B |
| Earnings growth (last year) | -46.78% |
| Earnings growth (this year) | -3.93% |
| Earnings growth (next 5 years) | +5.40% |
| Revenue growth (last year) | +2.10% |
| P/E ratio | 21.2 |
| Price/Sales | 4.86 |
| Price/Book | 3.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +0.13 | +0.17% |
| NVSNovartis | +1.92 | +2.53% |
| ABTAbbott Laboratories | +0.65 | +0.85% |
| LLYEli Lilly and Co | +0.51 | +0.43% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $0.75 |
| Annual revenue (last year) | $53.6B |
| Annual profit (last year) | $11.2B |
| Net profit margin | 20.77% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Director, Chief Executive & Operating Officer Albert Bourla |
Chief Financial Officer & EVP-Business Operations Frank A. D'Amelio |
Corporate headquarters New York, New York |
